Improving Treatments for Diseases with Unmet Medical Need
Mucpharm - Summary
Entering clinical phase 2 for first application in oncology – intratumoural & intraperitoneal BromAc® in pseudomyxoma peritonei
Significant synergy seen in combination with chemotherapy and other targeted oncology agents
US FDA & EMA orphan designations for peritoneal mucinous tumours
Application of BromAc® with chemotherapy during hyperthermic intraperitoneal chemotherapy (HIPEC) with Mitomycin C is progressing towards phase 1b
Phase 1 safety of airway use of BromAc® completed, progressing towards phase 1b in muco-obstructive respiratory diseases and mechanically ventilated patients
Positive outcomes from preclinical studies in bacterial biofilms and fungal infections, identified by the World Health Organisation as priority pathogens, with BromAc®
Pipeline of oncology and respiratory treatments under early stage (pre-clinical) investigation
Internationally known and highly regarded research team with clinical and preclinical collaborators in each program area worldwide
Our Mission
To provide more effective treatment options for patients with mucin related diseases
Mucpharm is a specialised company focused on the treatment of mucin-containing and secreting conditions. Our company was established by a group of clinicians and scientists, who specialise in treating patients with advanced cancers of the peritoneum.
Mucpharm’s aim is to develop BromAc® for a rare disease in oncology, known as pseudomyxoma peritonei. We have grown and continue to focus on the treatment of mucin-containing and secreting cancers and other disease conditions, with BromAc® as our lead compound.
Many diseases involve mucin. Mucin is a barrier to cancer and targeted therapies due to promoting chemoresistance, invasiveness and metastasis. We have demonstrated in a number of studies that BromAc® removes mucin from cancer cells, sensitizing them to chemotherapy and other treatment agents. The efficacy of BromAc® in advanced cancers is being explored in phase 2 studies.
The role of mucin in a range of respiratory diseases is already established, leading to a decline in respiratory function and secondary infections in some cases. The role of BromAc® in these conditions is being investigated in clinical trials.
We seek to continue to grow scientific and clinical research based in Australia and engage in global partnerships to strengthen the development of products for unmet medical need and rare disease areas
Our Team
Having worked together for many years, we share common goals and aspirations to develop new and improved treatments for difficult to treat cancers, respiratory diseases and infections. Our goal is to improve the quality of life and overall survival of patients with rare diseases and unmet medical need areas and continue to grow as a research and pharmaceutical development team.